Novo Nordisk said on Monday it has launched its popular obesity drug Wegovy in China, the world's second-largest ...

Novo Nordisk said on Monday it has launched its popular obesity drug Wegovy in China, the world's second-largest ...

Novo Nordisk (NVO) has reportedly launched its popular weight-loss drug Wegovy in China ahead of a rival drug by Eli Lilly ...

EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' ...

Novo Nordisk is gradually ending production of human insulin pens, the drugmaker told Reuters, as it spends billions to ramp ...

Novo Nordisk's Wegovy launch in China begins in Shanghai at $194 per four-injection pack, significantly cheaper than U.S.

Novo Nordisk said Monday it has launched its popular obesity drug Wegovy in China, the world’s second-largest pharmaceuticals market where it estimates more than 180 million people live with obesity.

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...

Wegovy is being made available to Chinese patients five months after its approval in the country. Novo will sell the medicine ...

The company narrowed its full-year guidance as its blockbuster weight-loss drug soars in popularity.

Novo Nordisk on Wednesday reported third quarter earnings broadly in line with expectations and narrowed its 2024 full-year ...